DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Cefdinir
Cap: 16-21 a 13-23 b 89 c 11-15 d 1.6-2.1 d 1.4-1.5 Cap: 3 ± 0.7 e Cap:2.9 ± 1.0
μg/mL e
Susp: 25 a b RD Susp: 2 ± 0.4 e
b Iron Susp: 3.9 ± 0.6
μg/mL e
a
Bioavailability following ingestion of a capsule (Cap) or suspension (Susp) formulated dose.
b
Determined after a single oral dose. c Lower plasma protein binding (71-74%) reported in
patients undergoing dialysis. d CL/F and V/F reported. e Following ingestion of a single 600-
mg capsule given to adults or a 14-mg/kg suspension dose given to children (6 months to 12
years). No accumulation after multiple dosing.
Cefepime a
— 80 16-19 1.8 (1.7-2.5) b 0.26 (0.24-0.31) d 2.1 (1.3-2.4) b — 65 ± 7 μg/mL e
b RD c
a RD c
a
Data from healthy adult patients. Available only in parenteral form. b Median (range) of
reported CL and t 1/2
values from 16 single-dose studies. c Mild renal impairment. d Median
(range) of reported V ss
from 6 single-dose studies. e Following a 1-g IV dose.
Ceftazidime
References: Guay DR. Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended
spectrum cephalosporin. Pediatr Infect Dis J, 2000, 19:S141–S146. PDR58, 2004, p. 503.
Tomino Y, et al. Pharmacokinetics of cefdinir and its transfer to dialysate in patients with
chronic renal failure undergoing continuous ambulatory peritoneal dialysis.
Arzneimittelforschung, 1998, 48:862–867.
References: Okamoto MP, et al. Cefepime clinical pharmacokinetics. Clin Pharmacokinet,
1993, 25:88–102. Rybak M. The pharmacokinetic profile of a new generation of parenteral
cephalosporin. Am J Med, 1996, 100:39S–44S.
— 84 ± 4 21 ± 6 CL = 1.05CL cr
+ 0.12 0.23 ± 0.02 1.6 ± 0.1 IM: 0.7-1.3 a IV: 119-146 μg/mL a
IM: 91 i CF i CF, Burn i RD, CF a RD, Prem, Neo, IM: 29-39 μg/mL a
a Aged, Burn Aged
i CF
a
Range of mean data from different studies following a 1-g bolus IV or IM dose given to
healthy adults.
Reference: Balant L, et al. Clinical pharmacokinetics of the third generation cephalosporins.
Clin Pharmacokinet, 1985, 10:101–143.
(Continued)
APPENDIX II
DESIGN AND OPTIMIZATION OF DOSAGE REGIMENS: PHARMACOKINETIC DATA
1911